Letolizumab Explained
Type: | mab |
Mab Type: | scFv |
Source: | zu/o |
Target: | tumor necrosis factor-related activation protein |
Cas Number: | 1450981-87-9 |
Atc Prefix: | none |
C: | 1734 |
H: | 2688 |
N: | 466 |
O: | 538 |
S: | 10 |
Unii: | 449MIE2SD6 |
Kegg: | D11122 |
Synonyms: | BMS-986004 |
Chemspiderid: | none |
Letolizumab (INN;[1] development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[2]
This drug was developed by Bristol-Myers Squibb.[3]
References
- . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116 . WHO Drug Information . 30 . 4 . 2016 .
- Budamakuntla L, Shree-Lakshmi HV, Bansal A, Venkatarayaraju SK . Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India . Psoriasis: Targets and Therapy . 9 . 19–27 . 2019 . 31119094 . 6501705 . 10.2147/PTT.S154073 . free .
- https://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fletolizumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab